Verastem Inc ((VSTM)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Verastem Inc. is conducting a Phase 1/2a clinical study titled A Phase 1/2a, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors. The study aims to evaluate the safety and efficacy of the drug VS-7375, both alone and in combination with Cetuximab, in treating patients with advanced solid tumors that have a KRAS G12D mutation. This research is significant as it targets a specific genetic mutation known to drive cancer progression.
The interventions being tested include VS-7375, a selective oral KRAS G12D inhibitor, and Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR). These treatments are designed to inhibit tumor growth by targeting specific pathways involved in cancer cell proliferation.
The study is interventional with a non-randomized, sequential model, and no masking is involved. Its primary purpose is treatment-focused, aiming to determine the recommended phase 2 dose and assess the efficacy of the interventions in patients with specific mutations.
The study began on June 24, 2025, with the primary completion and estimated completion dates yet to be announced. The last update was submitted on July 15, 2025. These dates are crucial for tracking the study’s progress and anticipating results that could influence clinical practices and market dynamics.
This clinical update could impact Verastem’s stock performance positively if the results show promise, potentially increasing investor confidence. The study’s focus on a specific mutation may also position Verastem favorably against competitors in the oncology sector, highlighting its innovative approach to cancer treatment.
The study is currently recruiting, and further details can be found on the ClinicalTrials portal.